Table 2.

Correlation between clinicopathological factors and early progression during nivolumab.

Univariate Analysis			Multivariate Analysis
Characteristic	OR 1 (95% CI 2)	p	OR (95% CI)	p
Sex
female vs. male	3.83 (0.75–19.56)	0.106	4.82 (0.62–37.50)	0.133
Age	0.99 (0.94–1.04)	0.580	0.94 (0.87–1.02)	0.151
Alcohol history	1.39 (0.44–4.44)
yes vs. not		0.575	1.26 (0.26–7.96)	0.775
Smoking
Yes vs. not	0.36 (0.12–1.11)	0.075	0.32 (0.07–1.49)	0.147
Subsite
Oropharynx	1.31 (0.32–5.43)	0.711	2.38 (0.31–18.18)	0.403
Hypopharynx	0.73 (0.14–3.82)	0.707	0.60 (0.07–4.89)	0.635
Oral cavity	1.82 (0.42–7.94)	0.427	1.42 (0.22–9.02)	0.713
Larynx	1.00 (1.00–1.00)		1.00 (1.00–1.00)	0.382
Others	0.36 (0.05–2.50)	0.303	0.27 (0.01–5.03)
Locoregional treatment
yes vs. not	5.42 (1.67–17.56)	0.005 4	5.41 (1.02–28.74)	0.048 5
Platinum-CT 3
Cisplatin	0.42 (0.14–1.28)	0.127	0.31 (0.08–1.25)	0.099
Carboplatin	1.00 (1.00–1.00)		1.00 (1.00–1.00)
Unknown	0.42 (0.07–2.55)	0.347	0.30 (0.02–4.38)	0.378

¹ OR: odds ratio. ² CI: confidential interval. ³ CT: chemotherapy. ^4,5 Statistical significance was set at p < 0.05.